Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-06-05
2011-12-06
Tsang, Cecilia J (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000
Reexamination Certificate
active
08071553
ABSTRACT:
Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.
REFERENCES:
patent: 7192930 (2007-03-01), Hefeneider et al.
patent: 7557086 (2009-07-01), Hefeneider et al.
patent: 2005/0244430 (2005-11-01), O'Neill et al.
Akira, “Mammalian Toll-like receptors,”Curr. Opin. Immunol., 15:5-11, (2003).
Almawi and Melemedjian, “Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids,”J. Mol. Endocrinol., 28:69-78, (2002).
Andreakos et al., “Cytokines and anti-cytokine biologicals in autoimmunity: present and future,”Cytokine Growth Factor Rev., 13:299-313, (2002).
Bartfai et al., “A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses,”Proc. Natl. Acad. Sci. U.S.A., 100:7971-7976, (2003).
Barton and Medzhitov, “Linking Toll-like receptors to IFN-α/β expression,”Nat. Immunol., 4:432-433, (2003).
Barzilai et al., “Middle ear effusion II-6 concentration in bacterial and non-bacterial acute otitis media,”Acta Paediatr, 89:1068-1071, (2000).
Basu and Fenton, “Toll-like receptors: function and roles in lung disease,”Am. J. Physiol. Lung Cell Mol. Physiol. 286:L887-892, (2004).
Bellows et al., “Vaccinia virus-induced inhibition of nitric oxide production,”J. Surg. Res., 111:127-135, (2003).
Bone et al., “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis,”Chest, 101:1644-1655, (1992).
Bowie et al., “A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling,”Proc. Natl. Acad. Sci. U.S.A., 97:10162-10167, (2000).
Brint et al., “ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance,”Nat. Immunol., 5:373-379, (2004).
Chuang and Ulevitch, “Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors,”Nat. Immunol., 5:495-502, (2004).
Daly et al., “Chronic Otitis Media with Effusion,”Pediatrics in Review, 20:85-93, (1999).
Daun and Fenton, “Interleukin-1fToll receptor family members: receptor structure and signal transduction pathways,”J. Interferon Cytokine Res., 20:843-855, (2000).
Delgado et al., “PACAP in immunity and inflammation,”Ann. N. Y. Acad. Sci., 992: 141-157, (2003).
Fan and Malik Toll-like receptor-4(TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors,Nat. Med., 9:315-321, (2003).
Granucci et al., “Inducible II-2 production by dendritic cells revealed by global gene expression analysis,”Nat. Immunol., 2:882-888, (2001).
Harte et al., “The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense,”J. Exp. Med., 197:343-351, (2003).
Hayashi et al., “The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5,”Nature410: 1 099-11 03, (2001).
Hemmi et al., “A Toll-like receptor recognizes bacterial DNA,”Nature, 408:740-745, (2000).
Hoshino et al., “Cutting Edge: Toll-like receptor 4 (TLR4)-deficient mice are hypreresponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product,”J. Immunol., 162: 3749-3752, (1999).
Ikezoe et al., PC-SPES: A potent inhibitor of nuclear factor-kB rescues mice from lipopolysaccharide-induced septic shock,Mol. Pharmacol., 64:1521-1529, (2003).
Janssens and Beyaert, “Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members,”Mol. Cell., 11:293-302, (2003).
Karasen et al., “Effect of web 2170 BS, platelet activating factor receptor inhibitor, in the guinea pig model of middle ear inflammation,”Ann. Otol. Rhiniol Laryngol., 109:549-553, (2000).
Kopp and Ghosh, “Inhibition of NF-kappa B by sodium salicylate and aspirin,”Science, 265:956-959, (1994).
Krieg, “CpG motifs in bacterial DNA and their immune effects,”Ann. Rev. Immunol. 20:709-760, (2002).
Kubba et al., “The aetiology of otitis media with effusion: a review,”Clin. Otolaryngol, 25:181-194, (2000).
McCoy et al., “Activation of RAW264.7 macrophages by bacterial DNA and lipopolysaccharide increases cell surface DNA binding and internalization,”J Biol. Chem., 279:17217-17223, (2004).
McCoy et al., “Identification of a Peptide Derived form Vaccinia Virus A52R Protein That Inhibits Cvtokine Secretion in Response to TLR-Dependent Signaling and Reduces In Vivo Bacterial-Induced Inflammation,”The Journal of Immunology, 174:3006-3014, (2005).
Meng et al., “Antagonistic antibody prevents Toll-like receptor 2-driven lethal shock-like syndromes,”J. Clin. Invest., 113:1473-1481, (2004).
Ng and Henikoff, “Predicting Deleterious Amino Acid Substitutions,”Genome Research, 11:863-874, (2001).
O'Brien, “SEPSIS,”The American Journal of Medicine, 120:1012-1022, (2007).
O'Neill, “The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defense,”Biochem. Soc. Trans., 28:557-563, (2000).
Office action, dated Mar. 20, 2008, from co-pending U.S. Appl. No. 11/834,506.
Office action, dated Nov. 26, 2008, from co-pending U.S. Appl. No. 11/834,506.
O'Neill, “Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases,”Curr. Opin. Pharm., 3:396-403, (2003).
Ozato et al., “Toll-like receptor signaling and regulation of cytokine gene expression in the immune system,”BioTechniques, Oct. Suppl: 66-75, (2002).
Rittirsch et al., “The disconnect between animal models of species and human sepsis,”The Journal of Leukocyte Biology, 81:137-143, (2007).
Schnare et al., “Toll-like receptor control activation of adaptive immune responses,”Nat. Immuno., 2:947-950, (2001).
Sweet et al., “A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression,”J. Immunol., 166:6633-6639, (2001).
Takeda and Akira, “TLR signaling pathways,”Semin. Immunol., 16:3-9, (2004).
Takeda et al., “Toll-like receptors,”Ann. Rev. Immunol. 21:335-378, (2003).
Trinchieri, “Interleukin-12: a cytokine at the interface of inflammation and immunity,”Adv. Immunol., 70:83-243, (1998).
Tsung et al., “A novel inhibitory peptide of toll-like receptor signaling limits lipolysaccharide-induced produced of inflammatory mediators and enhances survival in mice,”Shock, 27(4):364-369, (2007).
Voet and Voet.,Biochemistry, 2nd Edition., 235-241, (1995).
Wender et al., “The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters,”Proc. Nat. Acad. Sci. U.S.A., 97:13003-13008, (2000).
Yi and Krieg. “Cutting Edge: Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA,”J. Immunol., 161 :4493-4497, (1998).
Yi et al., “Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular Signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response,”J. Immunol., 168:4711-4720, (2002).
Zuany-Amorim et al., “Toll-like receptors as potential therapeutic targets for multiple diseases,”Nat. Rev. Drug Discov., 1:797-807, (2002).
Hefeneider Steven H.
McCoy Sharon L.
Gudibande Satyanarayana
Klarquist & Sparkman, LLP
Oregon Health & Science University
The United States of American as represented by the Department o
Tsang Cecilia J
LandOfFree
Method and peptide for regulating cellular activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and peptide for regulating cellular activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and peptide for regulating cellular activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293581